Latest News for ERNA
Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical study validated the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined with PD-1 checkpoint inhibition, reinforcing earlier findings.
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluation IND submission planned for the third quarter of 2026 with first-in-human Phase 1 study anticipated to begin in the fourth quarter of…
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ERNA.
U.S. House Trading
No House trades found for ERNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.